<DOC>
	<DOCNO>NCT02643511</DOCNO>
	<brief_summary>Whole gland LDR brachytherapy well establish modality treat low risk prostate cancer . Treatment focal manner advantage reduce toxicity surround organ . AIM : To determine utility focal LDR brachytherapy form hemiablative treatment localized prostate cancer demonstrate feasibility delivery prescription dose half prostate term meet standard dosimetric parameter respect low tolerance dos adjacent normal organ . To determine acute late rectal , urinary sexual toxicity procedure . To assess change baseline QOL indicator specific time interval use validated international questionnaire [ International Prostate Symptom Score ( IPSS ) , International Index Erectile Function ( IIEF ) , Expanded Prostate Cancer Index ( EPIC ) ] treatment . To evaluate local tumour control term biopsy outcomes focal brachytherapy 36 month treatment . To compare target coverage relative dos rectum urethra patient perform hemigland treatment plan vs Whole gland treatment planning . STUDY DESIGN : Multi-institution prospective trial determine whether hemiablative treatment LDR prostate cancer dosimetrically safe feasible.This study record data 20 patient ipsilateral low low tier intermediate risk disease.The study record quality life parameter particular term urinary , rectal sexual function side effect . INTERVENTION : - Baseline Transperineal Template guide map prostate biopsy &gt; 20 core ( require already perform ) - Multiparametric MRI within 3 month prior registration 18 &amp; 36 month . - Hemigland prostate region target prescription dose receive 144 Gy Iodine125 ( I125 ) . - The quality life assessment focus erectile function , urinary function , bowel function , general health relate quality life - Postimplant CT Planning day 30 implant quality assurance . MEASUREMENT OF ENDPOINTS : Dosimetric parameter record , Toxicity QOL evaluation form , PSA follow biopsy 36 month assess local control .</brief_summary>
	<brief_title>Hemiablative Focal Brachytherapy Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patients must histologically prove adenocarcinoma prostate . 2 . Patients must low lowtier intermediate prostate cancer Low risk prostate cancer patient must : Clinical stage ≤ T2a , Gleason score =6 iPSA ≤ 10 ng/ml &lt; 25 % core positive , &lt; 50 % cancer core involve Low tier Intermediate risk patient may : Clinical stageT2a Gleason score ≤ 3+4=7 PSA ≤ 10 ng/ml &lt; 25 % core positive , &lt; 50 % cancer core 3 . Patients must fit general anesthetic . 4 . Patients must unilateral disease biopsy 5 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 6 . Men ≥ 65 year age life expectancy estimate &gt; 10 year . 7 . Patients must contraindications interstitial prostate brachytherapy . 8 . Patients anticoagulant therapy must able stop therapy safely least 7 day . 9 . Patients must contraindications MRI 10 . IPSS &lt; =16 1 . Does meet stag criterion low risk low tier intermediate risk prostate cancer 2 . Bilateral prostatic disease 3 . Prior hormonal therapy 4 . Prior Transurethral resection middle lobe resection 5 . Recent IPSS &gt; 6 . Unfit general anesthetic 7 . MRI contraindicate 8 . Unable cease anticoagulant therapy 9 . Life expectancy &lt; 10 year 10 . IPSS &gt; 16</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>